The U.S. Food and Drug Administration (FDA) has approved Yescarta, a Car-T cell therapy, for lymphoma patients. Developed by Kite Pharma and Gilead Sciences, a Leukemia Research Foundation sponsor, the therapy involves removing a patient's own immune T-cells, reengineering them to recognize and
A new medication for patients diagnosed with specific types of AML has been granted Fast Track designation by the U.S. FDA. learn more about Astellas' gilteritinib by clicking here.
You will find an update on the Leukemia Research Foundation's Medical Awards Luncheon, read about an LRF-funded researcher who has achieved continued success and hear from a centenarian LRF volunteer.
The US Food and Drug Administration (FDA) has approved the first CAR-T cell therapy for patients diagnosed with B-cell precursor acute lymphoblastic leukemia (A.L.L.) that is refractory or in second or later relapse. This is the first CAR-T cell therapy approved by the FDA. More details are
Blood Cancer Awareness Month starts Friday, September 1, 2017. You're invited to join the LRF in spreading awareness.
News about an LRF-funded researcher, an FDA panel weighs in on gene therapy, Blood Cancer Awareness Month and more in this issue.
(NORTHFIELD, Ill.) The Leukemia Research Foundation (LRF) is proud to announce the recipients of its 2017-2018 funding of blood cancer research. The LRF awards one-year, 100,000 grants to support research projects that will result in a better understanding blood cancers, as well as bolster the
This is the July 2017 edition of the LRF's eNewsletter.
Nearly 2,000 runners, walkers, volunteers, and survivors of blood cancers beat the heat on Thursday, June 15 to participate in the 23rd Annual ABC 7 Gibbons 5K Run and 3K Walk in Chicago’s Grant Park to benefit the Northfield, Ill.-based Leukemia Research Foundation (LRF). The run start was
Funded by the LRF in 2015-2016, Paul A. Spagnuolo, Ph.D. is currently researching how a compound found in avocado pits can kill leukemia stem cells. Dr. Spagnuolo just received a 100,000 from the Ontario Institute for Cancer Research to continue studying the compound as a possible treatment for